Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.
← catalyst calendarNCT07279935 · readout in 1,368 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Sites
33
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-26 | actual | When the study began enrolling |
| Primary completion | 2030-05-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-05-18 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-small Cell Lung Cancer
Intervention
- Drug: Osimertinib+cisplatin or carboplatin + pemetrexed Edit — also filed as Cohort1
Primary outcome
what the primary-completion date above is the date OFTo assess the efficacy of osimertinib + chemotherapy by evaluation of PFS in patients who had distant recurrence after adjuvant osimertinib.
measured Approximately 52 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed